Announcement of Sobi's Q4 and FY 2024 Report
Sobi plans to unveil its report regarding the fourth quarter and full year of 2024 on February 5, 2025, at 08:00 CET. This report will provide valuable insights into the company's financial performance over the entire year.
Conference Call Invitation
On the same day as the report release, Sobi invites investors, analysts, and members of the media to join a conference call at 14:30 CET, which corresponds to 13:30 GMT and 08:30 EST. This session will feature a comprehensive presentation of the quarterly results followed by a Q&A segment, allowing participants to engage directly with company representatives.
How to Access the Conference Call
The conference call can be streamed live or listened to later on Sobi's official website. Participants can access the presentation slides shortly before the call, enhancing the experience for those attending.
Dial-In Details for Participants
For professionals eager to take part in the conference call, they can use the following local dial-in numbers:
Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13
About Sobi
Sobi, a specialized international biopharmaceutical company, is dedicated to improving the lives of individuals grappling with rare diseases. The firm emphasizes reliability and innovation in providing access to medicines in areas such as hematology, immunology, and specialty care. Recognized for its commitment, Sobi employs approximately 1,800 professionals across Europe, North America, the Middle East, Asia, and Australia. The company achieved a remarkable revenue of SEK 22.1 billion recently. Sobi is listed on Nasdaq Stockholm under the ticker STO: SOBI.
Continued Commitment to Innovation
Sobi remains focused on delivering innovative treatments that transform patient care. By investing in research and development, the company strives to expand its portfolio of therapies aimed at managing complex health issues. The dedication to rare and debilitating diseases sets Sobi apart, as it continually seeks ways to enhance quality of life for patients globally.
Contacting Sobi
For inquiries regarding investor relations, individuals can find helpful contact details on Sobi's official website. Additionally, media representatives can find dedicated media contacts available for further communication. The goal is to ensure effective communication channels leading to informed discussions and timely updates.
Frequently Asked Questions
What is the purpose of Sobi's upcoming conference call?
The conference call is to present the financial results for Q4 and the full year of 2024, along with a Q&A session for participants.
How can I access the presentation from the conference call?
The presentation will be available live during the call and posted later on Sobi's official website.
What are the financial highlights of Sobi for 2023?
Sobi reported a revenue of SEK 22.1 billion, showcasing its strong performance in the biopharmaceutical sector.
What types of diseases does Sobi focus on?
Sobi specializes in treatments for rare and debilitating diseases, particularly in hematology, immunology, and specialty care.
How can investors find out more about Sobi's financial performance?
Investors can stay informed by participating in the conference call and reviewing the financial results published on Sobi's website.
